These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
126 related items for PubMed ID: 2505185
1. Kinetics of erythropoiesis in dialysis patients receiving recombinant erythropoietin treatment. Najean Y, Moynot A, Deschryver F, Zins B, Naret C, Jacquot C, Drueke T. Nephrol Dial Transplant; 1989; 4(5):350-5. PubMed ID: 2505185 [Abstract] [Full Text] [Related]
2. One year of rHuEPO therapy prolongs RBC survival and may stabilize RBC membranes despite natural progression of chronic renal failure to uremia and need for dialysis. Schwartz AB, Kelch B, Terzian L, Prior J, Kim KE, Pequinot E, Kahn SB. ASAIO Trans; 1990; 36(3):M691-6. PubMed ID: 2252785 [Abstract] [Full Text] [Related]
3. Is erythropoietin a survival factor for red blood cells? Polenakovic M, Sikole A. J Am Soc Nephrol; 1996 Aug; 7(8):1178-82. PubMed ID: 8866410 [Abstract] [Full Text] [Related]
5. Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment. Hughes RT, Cotes PM, Pippard MJ, Stevens JM, Oliver DO, Winearls CG, Royston JP. Br J Haematol; 1990 Jun; 75(2):268-73. PubMed ID: 2372513 [Abstract] [Full Text] [Related]
6. Erythropoiesis and erythrocyte age distribution in hemodialysis patients undergoing erythropoietin therapy. Hampl H, Riedel E, Scigalla P, Stabell U, Wendel G. Blood Purif; 1990 Jun; 8(3):117-25. PubMed ID: 2244989 [Abstract] [Full Text] [Related]
11. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin. Beguin Y, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G, Fillet G. Br J Haematol; 1995 Jan; 89(1):17-23. PubMed ID: 7833259 [Abstract] [Full Text] [Related]
13. The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis. Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJ, Meyer J. S Afr Med J; 1996 Aug; 86(8):952-5. PubMed ID: 8823420 [Abstract] [Full Text] [Related]
15. Erythrocyte metabolism during renal anemia treatment with recombinant human erythropoietin. Debska-Slizień A, Owczarzak A, Lysiak-Szydłowska W, Rutkowski B. Int J Artif Organs; 2004 Nov; 27(11):935-42. PubMed ID: 15636050 [Abstract] [Full Text] [Related]
16. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Cotes PM, Pippard MJ, Reid CD, Winearls CG, Oliver DO, Royston JP. Q J Med; 1989 Feb; 70(262):113-37. PubMed ID: 2594953 [Abstract] [Full Text] [Related]
17. Case management of the anemic patient. Epoetin alfa: focus on kinetic dosing. Keen ML. ANNA J; 1990 Aug; 17(4):318-9. PubMed ID: 2396859 [Abstract] [Full Text] [Related]
19. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Takeda A, Toda T, Shinohara S, Mogi Y, Matsui N. Am J Kidney Dis; 2002 Jul; 40(1):104-9. PubMed ID: 12087567 [Abstract] [Full Text] [Related]